IRIX
IRIDEX Corporation
Price Chart
Latest Quote
$1.19
+0.01 (+0.85%)
Current Price
| Previous Close | $1.18 |
| Open | $1.18 |
| Day High | $1.20 |
| Day Low | $1.18 |
| Volume | 22,715 |
Stock Information
| Shares Outstanding | 17.41M |
| Total Debt | $4.28M |
| Cash Equivalents | $4.59M |
| Revenue | $52.58M |
| Net Income | $-3.27M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $20.54M |
| EPS (TTM) | $-0.19 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $26.39M |
| Sales | $52.58M |
| Income | $-3.27M |
| Book/sh | $-0.07 |
| Cash/sh | $0.26 |
| Employees | 93 |
Financial Ratios
| Quick Ratio | 1.01 |
| Current Ratio | 1.92 |
| Debt/Eq | 90.36 |
Returns & Margins
| ROA | -5.38% |
| ROE | -56.54% |
| Gross Margin | 35.97% |
| Operating Margin | -2.75% |
| Profit Margin | -6.23% |
Ownership
| Insider Ownership | 28.86% |
| Institutional Ownership | 18.04% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 59.00 |
| PEG | 0.94 |
| P/S | 0.39 |
| P/B | -16.16 |
Analyst Data
| Recommendation | none |
| Target Price | $2.75 |
Technical Indicators
| SMA20 | $1.14 |
| SMA50 | $1.08 |
| SMA200 | $1.16 |
| RSI | 54.84 |
| ATR | 0.0429 |
| Shares Float | 11.35M |
| Short Float | 0.25% |
| Short Ratio | 0.50 |
| Volatility | 0.66 |
| Rel Volume | 0.63 |
Performance History
| Week | +0.85% |
| Month | +13.46% |
| Quarter | -11.28% |
| 6 Months | +14.56% |
| YTD | +0.85% |
| Year | +24.21% |
| 3 Years | -43.27% |
| 5 Years | -83.81% |
| 10 Years | -91.70% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $1.18 | 40,930 |
| 2026-06-24 | $1.19 | 22,700 |
| 2026-06-23 | $1.18 | 29,300 |
| 2026-06-22 | $1.18 | 106,500 |
| 2026-06-18 | $1.13 | 63,600 |
| 2026-06-17 | $1.17 | 35,600 |
| 2026-06-16 | $1.19 | 61,000 |
| 2026-06-15 | $1.18 | 67,200 |
| 2026-06-12 | $1.12 | 22,300 |
| 2026-06-11 | $1.12 | 29,400 |
| 2026-06-10 | $1.13 | 15,600 |
| 2026-06-09 | $1.12 | 87,500 |
| 2026-06-08 | $1.11 | 35,400 |
| 2026-06-05 | $1.09 | 137,400 |
| 2026-06-04 | $1.15 | 29,200 |
| 2026-06-03 | $1.15 | 91,700 |
| 2026-06-02 | $1.17 | 211,600 |
| 2026-06-01 | $1.11 | 125,000 |
| 2026-05-29 | $1.05 | 67,000 |
| 2026-05-28 | $1.03 | 20,700 |
| 2026-05-27 | $1.03 | 27,500 |
| 2026-05-26 | $1.04 | 102,400 |
About IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
đ° Latest News
IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product Growth
Zacks âĸ 2026-05-25T16:59:00Z
IRIDEX Corp (IRIX) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...
GuruFocus.com âĸ 2026-05-20T05:00:19ZIRIDEX Corporation Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-20T00:31:54Z
Top Analyst Reports for Microsoft, AbbVie & BHP
Zacks âĸ 2026-04-17T21:16:00Z
Iridex's Q4 Loss Narrows Year Over Year on Retina Sales Growth
Zacks âĸ 2026-04-01T17:23:00Z
IRIDEX Corporation Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-27T00:16:25Z
IRIDEX (IRIX) Q4 2025 Earnings Call Transcript
Motley Fool âĸ 2026-03-26T21:55:38Z
Iridex: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-26T20:37:06ZZacks Initiates Coverage of Iridex With Neutral Recommendation
Zacks âĸ 2026-01-02T14:35:00ZIRIDEX Corp (IRIX) Q3 2025 Earnings Call Highlights: Revenue Growth and Strategic Cost Management
GuruFocus.com âĸ 2025-11-12T05:00:56Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $33,448,000 | $29,167,000 | $30,062,000 | $31,604,000 |
| Cost Of Revenue | $33,448,000 | $29,167,000 | $30,062,000 | $31,604,000 |
| Total Revenue | $52,675,000 | $48,669,000 | $51,869,000 | $56,972,000 |
| Operating Revenue | $52,675,000 | $48,669,000 | $51,869,000 | $56,972,000 |
| Expenses | ||||
| Total Expenses | $55,246,000 | $56,971,000 | $61,876,000 | $64,514,000 |
| Other Income Expense | $-1,809,000 | $-540,000 | $527,000 | $60,000 |
| Other Non Operating Income Expenses | $-1,809,000 | $-540,000 | $527,000 | $60,000 |
| Operating Expense | $21,798,000 | $27,804,000 | $31,814,000 | $32,910,000 |
| Selling And Marketing Expense | $10,396,000 | $12,579,000 | $16,237,000 | $18,178,000 |
| General And Administrative Expense | $7,734,000 | $9,776,000 | $8,748,000 | $7,557,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-4,437,000 | $-8,910,000 | $-9,570,000 | $-7,547,000 |
| Normalized Income | $-4,437,000 | $-8,910,000 | $-9,570,000 | $-7,547,000 |
| Net Income From Continuing And Discontinued Operation | $-4,437,000 | $-8,910,000 | $-9,570,000 | $-7,547,000 |
| Total Operating Income As Reported | $-2,571,000 | $-8,302,000 | $-10,007,000 | $-7,542,000 |
| Net Income Common Stockholders | $-4,437,000 | $-8,910,000 | $-9,570,000 | $-7,547,000 |
| Net Income | $-4,437,000 | $-8,910,000 | $-9,570,000 | $-7,547,000 |
| Net Income Including Noncontrolling Interests | $-4,437,000 | $-8,910,000 | $-9,570,000 | $-7,547,000 |
| Net Income Continuous Operations | $-4,437,000 | $-8,910,000 | $-9,570,000 | $-7,547,000 |
| Pretax Income | $-4,380,000 | $-8,842,000 | $-9,480,000 | $-7,482,000 |
| Operating Income | $-2,571,000 | $-8,302,000 | $-10,007,000 | $-7,542,000 |
| Gross Profit | $19,227,000 | $19,502,000 | $21,807,000 | $25,368,000 |
| Per Share | ||||
| Diluted EPS | $-0.26 | $-0.54 | $-0.59 | $-0.47 |
| Basic EPS | $-0.26 | $-0.54 | $-0.59 | $-0.47 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,024,000 | $-6,878,000 | $-7,975,000 | $-6,158,000 |
| Reconciled Depreciation | $1,547,000 | $1,424,000 | $2,032,000 | $1,384,000 |
| EBITDA (Bullshit earnings) | $-1,024,000 | $-6,878,000 | $-7,975,000 | $-6,158,000 |
| EBIT | $-2,571,000 | $-8,302,000 | $-10,007,000 | $-7,542,000 |
| Diluted Average Shares | $16,934,000 | $16,439,000 | $16,128,000 | $15,938,000 |
| Basic Average Shares | $16,934,000 | $16,439,000 | $16,128,000 | $15,938,000 |
| Diluted NI Availto Com Stockholders | $-4,437,000 | $-8,910,000 | $-9,570,000 | $-7,547,000 |
| Tax Provision | $57,000 | $68,000 | $90,000 | $65,000 |
| Research And Development | $3,668,000 | $5,449,000 | $6,829,000 | $7,175,000 |
| Selling General And Administration | $18,130,000 | $22,355,000 | $24,985,000 | $25,735,000 |
| Other Gand A | $7,734,000 | $9,776,000 | $8,748,000 | $7,557,000 |
Fetched: 2026-06-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,973,000 | $-174,000 | $6,915,000 | $14,289,000 |
| Total Assets | $29,151,000 | $29,135,000 | $34,436,000 | $42,290,000 |
| Total Non Current Assets | $3,899,000 | $5,572,000 | $6,986,000 | $6,524,000 |
| Other Non Current Assets | $1,124,000 | $1,394,000 | $1,396,000 | $1,455,000 |
| Goodwill And Other Intangible Assets | $1,949,000 | $2,271,000 | $2,607,000 | $2,942,000 |
| Other Intangible Assets | $984,000 | $1,306,000 | $1,642,000 | $1,977,000 |
| Current Assets | $25,252,000 | $23,562,000 | $27,450,000 | $35,766,000 |
| Other Current Assets | $1,802,000 | $1,964,000 | $856,000 | $1,468,000 |
| Inventory | $7,877,000 | $10,817,000 | $9,906,000 | $10,608,000 |
| Receivables | $9,545,000 | $8,394,000 | $9,654,000 | $9,768,000 |
| Accounts Receivable | $7,613,000 | $5,951,000 | $6,727,000 | $6,229,000 |
| Allowance For Doubtful Accounts Receivable | $-112,000 | $-259,000 | $-146,000 | $-390,000 |
| Gross Accounts Receivable | $7,725,000 | $6,210,000 | $6,873,000 | $6,619,000 |
| Cash Cash Equivalents And Short Term Investments | $6,028,000 | $2,387,000 | $7,034,000 | $13,922,000 |
| Cash And Cash Equivalents | $6,028,000 | $2,387,000 | $7,034,000 | $13,922,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $4,532,000 | $4,643,000 | $2,746,000 | $1,769,000 |
| Long Term Debt And Capital Lease Obligation | $3,833,000 | $1,815,000 | $1,751,000 | $732,000 |
| Long Term Debt | $3,735,000 | $1,004,000 | - | - |
| Current Debt And Capital Lease Obligation | $699,000 | $2,828,000 | $995,000 | $1,037,000 |
| Net Debt | - | $351,000 | - | - |
| Current Debt | - | $1,734,000 | - | - |
| Other Current Borrowings | - | $1,734,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $24,229,000 | $27,038,000 | $24,914,000 | $25,059,000 |
| Total Non Current Liabilities Net Minority Interest | $11,021,000 | $10,479,000 | $11,940,000 | $12,606,000 |
| Other Non Current Liabilities | $387,000 | $314,000 | $164,000 | $26,000 |
| Non Current Deferred Liabilities | $6,801,000 | $8,350,000 | $10,025,000 | $11,742,000 |
| Current Liabilities | $13,208,000 | $16,559,000 | $12,974,000 | $12,453,000 |
| Current Deferred Liabilities | $3,677,000 | $3,488,000 | $3,329,000 | $3,379,000 |
| Payables And Accrued Expenses | $6,492,000 | $8,571,000 | $7,031,000 | $5,589,000 |
| Payables | $5,670,000 | $7,801,000 | $4,976,000 | $4,044,000 |
| Other Payable | $137,000 | $57,000 | $149,000 | $106,000 |
| Total Tax Payable | $31,000 | $150,000 | $100,000 | $65,000 |
| Accounts Payable | $5,385,000 | $6,985,000 | $4,499,000 | $3,858,000 |
| Equity | ||||
| Common Stock Equity | $-1,078,000 | $2,097,000 | $9,522,000 | $17,231,000 |
| Preferred Stock Equity | $6,000,000 | - | - | - |
| Total Equity Gross Minority Interest | $4,922,000 | $2,097,000 | $9,522,000 | $17,231,000 |
| Stockholders Equity | $4,922,000 | $2,097,000 | $9,522,000 | $17,231,000 |
| Gains Losses Not Affecting Retained Earnings | $-14,000 | $51,000 | $-52,000 | $-24,000 |
| Other Equity Adjustments | $-14,000 | $51,000 | $-52,000 | $-24,000 |
| Retained Earnings | $-92,446,000 | $-88,009,000 | $-79,042,000 | $-69,716,000 |
| Other | ||||
| Ordinary Shares Number | $17,306,521 | $16,636,380 | $16,252,813 | $15,989,662 |
| Share Issued | $17,306,521 | $16,636,380 | $16,252,813 | $15,989,662 |
| Tangible Book Value | $-3,027,000 | $-174,000 | $6,915,000 | $14,289,000 |
| Invested Capital | $2,657,000 | $4,835,000 | $9,522,000 | $17,231,000 |
| Working Capital | $12,044,000 | $7,003,000 | $14,476,000 | $23,313,000 |
| Capital Lease Obligations | $797,000 | $1,905,000 | $2,746,000 | $1,769,000 |
| Total Capitalization | $8,657,000 | $3,101,000 | $9,522,000 | $17,231,000 |
| Additional Paid In Capital | $91,208,000 | $89,881,000 | $88,444,000 | $86,802,000 |
| Capital Stock | $6,174,000 | $174,000 | $172,000 | $169,000 |
| Common Stock | $174,000 | $174,000 | $172,000 | $169,000 |
| Preferred Stock | $6,000,000 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $6,801,000 | $8,350,000 | $10,025,000 | $11,742,000 |
| Long Term Capital Lease Obligation | $98,000 | $811,000 | $1,751,000 | $732,000 |
| Current Deferred Revenue | $3,677,000 | $3,488,000 | $3,329,000 | $3,379,000 |
| Current Capital Lease Obligation | $699,000 | $1,094,000 | $995,000 | $1,037,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,340,000 | $1,672,000 | $1,619,000 | $2,448,000 |
| Current Accrued Expenses | $822,000 | $770,000 | $2,055,000 | $1,545,000 |
| Dueto Related Parties Current | $117,000 | $609,000 | $228,000 | $15,000 |
| Goodwill | $965,000 | $965,000 | $965,000 | $965,000 |
| Net PPE | $826,000 | $1,907,000 | $2,983,000 | $2,127,000 |
| Accumulated Depreciation | $-14,183,000 | $-13,983,000 | $-13,740,000 | $-13,559,000 |
| Gross PPE | $15,009,000 | $15,890,000 | $16,723,000 | $15,686,000 |
| Leases | $2,494,000 | $2,494,000 | $2,494,000 | $2,494,000 |
| Other Properties | $12,515,000 | $13,396,000 | $14,229,000 | $13,192,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $3,729,000 | $6,581,000 | $4,462,000 | $4,468,000 |
| Work In Process | $0 | $0 | $156,000 | $320,000 |
| Raw Materials | $4,148,000 | $4,236,000 | $5,288,000 | $5,820,000 |
| Duefrom Related Parties Current | $1,932,000 | $2,443,000 | $2,927,000 | $3,539,000 |
| Non Current Accrued Expenses | - | - | $138,000 | $106,000 |
| Long Term Provisions | - | - | - | - |
| Current Provisions | - | - | - | - |
Fetched: 2026-06-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-2,258,000 | $-7,298,000 | $-6,854,000 | $-9,805,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-2,115,000 | $-7,285,000 | $-6,745,000 | $-9,519,000 |
| Cash Flow From Continuing Operating Activities | $-2,115,000 | $-7,285,000 | $-6,745,000 | $-9,519,000 |
| Operating Gains Losses | $1,335,000 | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-143,000 | $-13,000 | $-109,000 | $-286,000 |
| Investing Cash Flow | $-143,000 | $-13,000 | $-109,000 | $-286,000 |
| Cash Flow From Continuing Investing Activities | $-143,000 | $-13,000 | $-109,000 | $-286,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $10,000,000 | $3,370,000 | $0 | $0 |
| Financing Cash Flow | $5,964,000 | $2,605,000 | $-5,000 | $-73,000 |
| Cash Flow From Continuing Financing Activities | $5,964,000 | $2,605,000 | $-5,000 | $-73,000 |
| Net Other Financing Charges | $-75,000 | $-551,000 | $-87,000 | $-94,000 |
| Net Preferred Stock Issuance | $6,000,000 | $0 | - | - |
| Preferred Stock Issuance | $6,000,000 | $0 | - | - |
| Net Common Stock Issuance | $4,000,000 | $3,370,000 | $0 | $0 |
| Common Stock Issuance | $4,000,000 | $3,370,000 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-3,961,000 | $-218,000 | $0 | - |
| End Cash Position | $6,028,000 | $2,387,000 | $7,034,000 | $13,922,000 |
| Beginning Cash Position | $2,387,000 | $7,034,000 | $13,922,000 | $23,852,000 |
| Effect Of Exchange Rate Changes | $-65,000 | $46,000 | $-29,000 | $-52,000 |
| Changes In Cash | $3,706,000 | $-4,693,000 | $-6,859,000 | $-9,878,000 |
| Proceeds From Stock Option Exercised | $0 | $4,000 | $82,000 | $21,000 |
| Net Issuance Payments Of Debt | $-3,961,000 | $-218,000 | $0 | - |
| Net Long Term Debt Issuance | $-3,961,000 | $-218,000 | $0 | - |
| Long Term Debt Payments | $-3,961,000 | $-218,000 | $0 | - |
| Net PPE Purchase And Sale | $-143,000 | $-13,000 | $-109,000 | $-286,000 |
| Purchase Of PPE | $-143,000 | $-13,000 | $-109,000 | $-286,000 |
| Change In Other Working Capital | $-1,565,000 | $-1,903,000 | $-1,723,000 | $868,000 |
| Change In Other Current Liabilities | $-571,000 | $-111,000 | $-794,000 | $-1,015,000 |
| Change In Other Current Assets | $270,000 | $2,000 | $-427,000 | $-1,185,000 |
| Change In Payables And Accrued Expense | $-1,647,000 | $1,401,000 | $473,000 | $-179,000 |
| Change In Accrued Expense | $799,000 | $-1,466,000 | $-381,000 | $-653,000 |
| Change In Payable | $-2,446,000 | $2,867,000 | $854,000 | $474,000 |
| Change In Account Payable | $-1,954,000 | $2,486,000 | $641,000 | $1,086,000 |
| Change In Prepaid Assets | $162,000 | $-1,108,000 | $612,000 | $-397,000 |
| Change In Inventory | $2,117,000 | $-911,000 | $644,000 | $-3,019,000 |
| Change In Receivables | $-1,151,000 | $1,260,000 | $358,000 | $-237,000 |
| Changes In Account Receivables | $-1,662,000 | $776,000 | $-254,000 | $196,000 |
| Other Non Cash Items | $227,000 | $328,000 | - | - |
| Stock Based Compensation | $775,000 | $1,243,000 | $1,650,000 | $1,621,000 |
| Asset Impairment Charge | $823,000 | $0 | - | - |
| Depreciation Amortization Depletion | $1,547,000 | $1,424,000 | $2,032,000 | $1,384,000 |
| Depreciation And Amortization | $1,547,000 | $1,424,000 | $2,032,000 | $1,384,000 |
| Depreciation | $1,547,000 | $1,424,000 | $2,032,000 | $1,384,000 |
| Net Income From Continuing Operations | $-4,437,000 | $-8,910,000 | $-9,570,000 | $-7,547,000 |
| Income Tax Paid Supplemental Data | - | $15,000 | $53,000 | $73,000 |
| Provisionand Write Offof Assets | - | - | $0 | $187,000 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Purchase Of Business | - | - | - | $0 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Sale Of PPE | - | - | - | - |
| Change In Working Capital | - | - | - | - |
Fetched: 2026-06-25